Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin‐Induced Nephrotoxicity

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical pharmacology and therapy

• Publication date

  2009-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/clpt.2009.139PMID 19625999PMCID PMC2746866
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone

  2009cited by this paper
• Pharmacogenetic Pathway Analysis of Docetaxel Elimination

  2009cited by this paper
• The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity.

  2009cited by this paper
• Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate

  2008cited by this paper
• Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin

  2008cited by this paper
• Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment.

  2008cited by this paper
• The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy.

  2008cited by this paper
• Interaction of Cisplatin with the Human Organic Cation Transporter 2

  2008cited by this paper
• Interaction of platinum compounds with the human organic cation transporter hOCT2 (SLC22A2)

  2008cited by this paper
• A Review on

  2008cited by this paper
• Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.

  2008cited by this paper
• Cisplatin Nephrotoxicity: A Review

  2007cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• Identification and Functional Characterization of Genetic Variants of Human Organic Cation Transporters in a Korean Population

  2007cited by this paper
• Activation and involvement of p53 in cisplatin-induced nephrotoxicity.

  2007cited by this paper
• Endotoxin and cisplatin synergistically stimulate TNF-α production by renal epithelial cells

  2007cited by this paper
• Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.

  2007cited by this paper
• Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G.

  2007cited by this paper
• The apical conjugate efflux pump ABCC2 (MRP2)

  2007cited by this paper
• Irinotecan‐induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein

  2007cited by this paper
• Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications

  2007cited by this paper
• Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

  2006cited by this paper
• Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family)

  2006cited by this paper
• Organic cation transporters are determinants of oxaliplatin cytotoxicity.

  2006cited by this paper
• Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition

  2006cited by this paper
• Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants.

  2006cited by this paper
• Characterization of Mice Lacking the Multidrug Resistance Protein Mrp2 (Abcc2)

  2006cited by this paper
• p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice.

  2005cited by this paper
• Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat.

  2005cited by this paper
• Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2.

  2005cited by this paper
• Cellular processing of platinum anticancer drugs

  2005cited by this paper
• Molecular and cellular physiology of renal organic cation and anion transport.

  2004cited by this paper
• Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2

  2004cited by this paper
• Population pharmacokinetics of cisplatin in adult cancer patients

  2004cited by this paper
• The SLC22 drug transporter family

  2004cited by this paper
• Nephrotoxicity of platinum complexes is related to basolateral organic cation transport.

  2004cited by this paper
• Protection of renal cells from cisplatin toxicity by cell cycle inhibitors.

  2004cited by this paper
• Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl-L-cysteine-cDDP by TEA and PAH in the renal proximal tubule

  2003cited by this paper
• Cisplatin: mode of cytotoxic action and molecular basis of resistance

  2003cited by this paper
• Organic cation transporters.

  2003cited by this paper
• Cisplatin nephrotoxicity.

  2003cited by this paper
• TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure.

  2003cited by this paper
• Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations

  2003cited by this paper
• Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function.

  2002cited by this paper
• Impaired Organic Anion Transport in Kidney and Choroid Plexus of Organic Anion Transporter 3 (Oat3 (Slc22a8)) Knockout Mice*

  2002cited by this paper
• TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity

  2002cited by this paper
• Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR)

  2002cited by this paper
• Interactions of Human Organic Anion Transporters and Human Organic Cation Transporters with Nonsteroidal Anti-Inflammatory Drugs

  2002cited by this paper
• Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene

  2001cited by this paper
• Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells.

  2001cited by this paper
• Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.

  2001cited by this paper
• Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.

  2000cited by this paper
• Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

  1999cited by this paper
• Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells.

  1999cited by this paper
• Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.

  1999cited by this paper
• Role of organic cation transporters in drug absorption and elimination.

  1998cited by this paper
• Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure.

  1998cited by this paper
• Renal toxicities of antineoplastic drugs and bone marrow transplantation.

  1997cited by this paper
• Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods

  1997cited by this paper
• Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1

  1997cited by this paper
• Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis.

  1996cited by this paper
• Comparison of ethanol plasma-protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations

  1996cited by this paper
• Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

  1996cited by this paper
• Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells.

  1995cited by this paper
• Comparative Adverse Effect Profiles of Platinum Drugs

  1995cited by this paper
• Cisplatin nephrotoxicity.

  1994cited by this paper
• Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.

  1993cited by this paper
• Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.

  1993cited by this paper
• Cisplatin nephrotoxicity: insights into mechanism.

  1987cited by this paper
• Cisplatin nephrotoxicity: role of filtration and tubular transport of cisplatin in isolated perfused kidneys.

  1987cited by this paper
• Effect of cisplatin on organic ion transport in membrane vesicles from rat kidney cortex.

  1985cited by this paper
• Mechanisms for the renal secretion of cisplatin.

  1984cited by this paper
• Mechanism of cisplatin nephrotoxicity.

  1983cited by this paper
• Mechanisms of renal excretion of cisdichlorodiamine platinum.

  1983cited by this paper
• Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum(II) to animals.

  1979cited by this paper
• Platinum Compounds: a New Class of Potent Antitumour Agents

  1969cited by this paper

• Germacrone Alleviates Cisplatin‐Induced Nephrotoxicity by Activating PI3K/Akt Signaling, Inhibiting Ras/MAPK Signaling, and Regulating Macrophage Polarization

  2026cites this paper
• Severe multiorgan toxicities after the first cycle of standard-dose etoposide-cisplatin therapy for metastatic nonseminoma successfully managed with etoposide-carboplatin: a case report.

  2026cites this paper
• A next generation physiologically-based kinetic model for quantitative in vitro to in vivo extrapolation of cisplatin-induced nephrotoxicity in humans.

  2026cites this paper
• Matricellular protein SMOC2 safeguards tubular integrity in acute kidney injury via integrin β3-dependent inhibition of CCND1-CDK4/6 axis

  2026cites this paper
• The organic cation transporters 1 and 2 mediate ethanolamine cellular efflux and control systemic phosphatidylethanolamine level

  2025cites this paper
• Both carvedilol and cimetidine alleviate cisplatin-induced nephrotoxicity via downregulating OCT2.

  2025cites this paper
• Molecular Mechanisms of Aminoglycoside-Induced Ototoxicity in Murine Auditory Cells: Implications for Otoprotective Drug Development

  2025cites this paper
• Beyond SGLT2: proximal tubule transporters as potential drug targets for chronic kidney disease

  2025cites this paper
• Enhancing therapeutic strategies and drug development for patients with kidney disease

  2025cites this paper
• Natural Compounds as Nephroprotective Agents: Therapeutic Potential Against Drug‐Induced Kidney Injury

  2025cites this paper
• Toxicidad en el adulto mayor desde la perspectiva de oncogeriatría y los cuidados paliativos. Parte 2

  2025cites this paper
• Bardoxolone methyl improves survival and reduces clinical measures of kidney injury in tumor-bearing mice treated with cisplatin

  2025cites this paper
• Using cimetidine to mitigate cisplatin-induced ototoxicity.

  2025cites this paper
• Mannitol versus furosemide for prevention of cisplatin-induced nephrotoxicity in a multicenter retrospective cohort study

  2025cites this paper
• Dysregulated lncRNAs in Cisplatin-Induced Nephrotoxicity and Their Association with Apoptosis and Autophagy: An Exploratory In Vitro Study

  2025cites this paper
• Nephrotoxicity of Conventional Chemotherapeutics: Part I - Platinum Compounds and Antimetabolite Agents.

  2025cites this paper
• Organic cation transporters 2: Structure, regulation, functions, and clinical implications.

  2025cites this paper
• Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia

  2025cites this paper
• Predicting OCT2/MATEs‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)

  2025cites this paper
• Advanced in vitro evaluation of drug-induced kidney injury using microphysiological systems in drug discovery and development.

  2025cites this paper
• EPHX1 and ERCC2 polymorphisms are associated with cisplatin-induced nephrotoxicity and prognosis in Thai cancer patients

  2025cites this paper
• Controlling nephron precursor differentiation to generate proximal-biased kidney organoids with emerging maturity

  2025cites this paper
• Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches

  2024cites this paper
• Visualization of intracellular ATP dynamics in different nephron segments under pathophysiological conditions using the kidney slice culture system.

  2024cites this paper
• Sex and the Kidney Drug‐Metabolizing Enzymes and Transporters: Are Preclinical Drug Disposition Data Translatable to Humans?

  2024cites this paper
• Visualization of intracellular ATP dynamics in the whole kidney under pathophysiological conditions using the kidney slice culture system

  2024influential citation
• Evaluation of Cisplatin-Induced Acute Kidney Injury in Patients Coprescribed Serotonin Receptor Antagonists: A Retrospective Analysis

  2024cites this paper
• Cisplatin caused highly delayed cytotoxicity in the immortalized cells derived from S3 segment of mouse kidney proximal tubules.

  2024cites this paper
• Effect of 7-ketocholesterol incorporation on substrate binding affinity and turnover rate of the organic cation transporter 2 (OCT2).

  2024cites this paper
• Therapeutic potential of mesenchymal stem cells in cisplatin-induced acute kidney injury via ASK-1/TXNIP pathway modulation

  2024cites this paper
• In silico analysis of potential inhibitors for breast cancer targeting 17beta‐hydroxysteroid dehydrogenase type 1 (17beta‐HSD1) catalyses

  2024cites this paper
• Three-dimensional culture of human proximal tubular epithelial cells for an in vitro evaluation of drug-induced kidney injury.

  2024cites this paper
• Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity

  2024cites this paper
• Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Induced Neuropathy and Mitochondrial Toxicity: Limitations of the Poly-γ Hypothesis and the Potential Roles of Autophagy and Drug Transport

  2024cites this paper
• Organic cation transporter 1 in the lacrimal gland facilitates the entry of systemic drugs causing ocular surface toxicity.

  2024cites this paper
• Comparative Analysis of the Physiological and Transport Functions of Various Sources of Renal Proximal Tubule Cells Under Static and Fluidic Conditions in PhysioMimix{trade mark, serif} T12 Platform.

  2024cites this paper
• Nephropathy induced by cisplatin results from mitochondrial disruption, impaired energy metabolism, altered expression of renal transporters, and accumulation of urinary toxins.

  2024cites this paper
• Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5‐HT3 Antagonist Antiemetic Drugs

  2024cites this paper
• Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury

  2024cites this paper
• Juzentaihoto alleviates cisplatin‐induced renal injury in mice

  2024cites this paper
• Augmented nephroprotective effect of liraglutide and rabeprazole via inhibition of OCT2 transporter in cisplatin-induced nephrotoxicity in rats.

  2023cites this paper
• The Role of Solute Carrier Transporters in Efficient Anticancer Drug Delivery and Therapy

  2023cites this paper
• Renal tubular transporter-mediated interactions between mirogabalin and cimetidine in rats

  2023cites this paper
• Polymorphic renal transporters and cisplatin’s toxicity in urinary bladder cancer patients: current perspectives and future directions

  2023cites this paper
• The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of Tyrosine Kinase Inhibitors

  2023cites this paper
• Drug Transporters at the Human Blood-Testis Barrier

  2023cites this paper
• Insight into Risk Factors, Pharmacogenetics/Genomics, and Management of Adverse Drug Reactions in Elderly: A Narrative Review

  2023cites this paper
• Cisplatin Nefrotoxicity and Treatment Approaches

  2023cites this paper
• Navigating the kidney organoid: insights into assessment and enhancement of nephron function.

  2023cites this paper
• Macrophage Depletion Protects Against Cisplatin-Induced Ototoxicity and Nephrotoxicity

  2023cites this paper
• Carbon Monoxide-Loaded Red Blood Cell Prevents the Onset of Cisplatin-Induced Acute Kidney Injury

  2023cites this paper
• Identification of Novel and Early Biomarkers for Cisplatin-Induced Nephrotoxicity and the Nephroprotective Role of Cimetidine using a Pharmacometabolomic-based Approach Coupled with In Vitro Toxicodynamic Modeling and Simulation.

  2023cites this paper
• Renal pharmacokinetic adaptation to cholestasis causes increased nephrotoxic drug accumulation by Mrp6 downregulation in mice.

  2023cites this paper
• Systematic Critical Review of Genetic Factors Associated with Cisplatin-induced Ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 Update

  2023cites this paper
• European standard clinical practice recommendations for children and adolescents with Primary and Recurrent osteosarcoma

  2023cites this paper
• Development of a new drug candidate for the inhibition of Lassa virus glycoprotein and nucleoprotein by modification of evodiamine as promising therapeutic agents

  2023cites this paper
• Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022

  2023cites this paper
• Interaction of systemic drugs causing ocular toxicity with organic cation transporter: an artificial intelligence prediction

  2023cites this paper
• Role of Mouse Organic Cation Transporter 2 for Nephro- and Peripheral Neurotoxicity Induced by Chemotherapeutic Treatment with Cisplatin

  2023cites this paper
• The underlying mechanisms of cisplatin-induced nephrotoxicity and its therapeutic intervention using natural compounds

  2023cites this paper
• The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage

  2023cites this paper
• Genetic variation in organic cation transporters and considerations in drug development

  2023cites this paper
• Electrolytes Play a Role in Detecting Cisplatin-Induced Kidney Complications and May Even Prevent Them—Retrospective Analysis

  2023cites this paper
• Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis

  2023cites this paper
• Cisplatin in Liver Cancer Therapy

  2023cites this paper
• Apigenin and kaempferol as novel renoprotective agent against cisplatin-induced toxicity: an in vitro study

  2022cites this paper
• Evaluation of Platinum Anticancer Drug-Induced Kidney Injury in Primary Culture of Rat Kidney Tissue Slices by Using Gas-Permeable Plates.

  2022cites this paper
• The Interplay between Uremic Toxins and Albumin, Membrane Transporters and Drug Interaction

  2022cites this paper
• Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K).

  2022cites this paper
• Rescue of Misfolded Organic Cation Transporter 3 Variants

  2022cites this paper
• Intravenous Administration of Cisplatin with Magnesium Sulfate Supplement May Prevent Kidney Toxicity in Rats: The Role of Gender and Magnesium Sulfate Dose

  2022cites this paper
• Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives

  2022cites this paper
• Prevention of cisplatin-induced nephrotoxicity by kidney-targeted sirna delivery.

  2022cites this paper
• Effect of Polymorphisms in Drug Transporters on Cisplatin Efficacy and Nephrotoxicity in Paediatric Osteosarcoma

  2022cites this paper
• Cisplatin nephrotoxicity: new insights and therapeutic implications

  2022cites this paper
• SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

  2022cites this paper
• Pharmacodynamic Modeling to Evaluate the Impact of Cimetidine, an OCT2 Inhibitor, on the Anticancer Effects of Cisplatin

  2022cites this paper
• Wnt/β-Catenin inhibitor pyrivinium attenuates cisplatininduced acute kidney injury by possibly reducing platinum uptake and accumulation mediated by reduced OCT-2 expressions.

  2022cites this paper
• The Cannabinoid-2 receptor agonist, 1-phenylisatin, protects against cisplatin-induced nephrotoxicity in mice.

  2022cites this paper
• Special Section on New Era of Transporter Science — Minireview Emerging Roles of the Human Solute Carrier 22 Family S

  2022cites this paper
• Apical Medium Flow Influences the Morphology and Physiology of Human Proximal Tubular Cells in a Microphysiological System

  2022cites this paper
• Evaluation of the binding mode of a cytotoxic dinuclear nickel complex to two neighboring phosphates of the DNA backbone.

  2022cites this paper
• Loss of the Volume-regulated Anion Channel Components LRRC8A and LRRC8D Limits Platinum Drug Efficacy

  2022cites this paper
• Loss of sphingosine kinase 2 protects against cisplatin induced-kidney injury.

  2022cites this paper
• Repositioning of Lansoprazole as a Protective Agent Against Cisplatin-Induced Ototoxicity

  2022cites this paper
• Transporters and Toxicity: Insights From the International Transporter Consortium Workshop 4

  2022cites this paper
• Genome-Wide Analyses of Nephrotoxicity in Platinum-Treated Cancer Patients Identify Association with Genetic Variant in RBMS3 and Acute Kidney Injury

  2022cites this paper
• Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies.

  2022cites this paper
• Cisplatin-induced nephrotoxicity in childhood cancer: comparison between two countries

  2022cites this paper
• Mechanistic insights into the primary and secondary alterations of renal ion and water transport in the distal nephron

  2022cites this paper
• Targeting EGFR, RSK1, RAF1, PARP2 and LIN28B for several cancer type therapies with newly synthesized pyrazole derivatives via a computational study

  2022cites this paper
• The protective effect of rabeprazole on cisplatin-induced apoptosis and necroptosis of renal proximal tubular cells.

  2022cites this paper
• Genetic Risk Factors for Adverse Drug Reactions

  2022cites this paper
• Decreased kidney mitochondrial content and PGC-1α following repeated low-dose cisplatin-induced kidney injury.

  2022cites this paper
• How platinum-induced nephrotoxicity occurs? Machine learning prediction in non-small cell lung cancer patients

  2022cites this paper
• High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3

  2022cites this paper
• Current Understanding of Membrane Transporters as Regulators or Targets for Cisplatin-Induced Hearing Loss

  2021influential citation
• Mouse Models of Acute Kidney Injury

  2021cites this paper
• The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage

  2021cites this paper
• Cisplatin chemotherapy and renal function.

  2021cites this paper